This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sierra, C. Articles by Ruilope, L. M Search for Related Content PubMed PubMed Citation Articles by Sierra, C. Articles by Ruilope, L. M Social Bookmarking                         What's this?

Review: Role of the selective aldosterone receptor blockers in arterial hypertension

Hypertension Unit, Hospital Clinic, Barcelona, Spain

Luis M Ruilope

Hypertension Unit, Hospital Doce de Octubre, Madrid, Spain, Luis_M_Ruilope{at}teleline.es

Aldosterone can cause cardiovascular injury in animals and men. The aldosterone blocker, spironolactone, has been shown to reduce mortality in patients with congestive heart failure. The use of this drug in arterial hypertension has been limited by the high frequency of adverse effects. Recently published data with a new aldosterone blocker, eplerenone, have confirmed the benefits of aldosterone blockade in patients post-myocardial infarction, as well as in the regression of left ventricular hypertrophy in hypertensive patients and of microalbuminuria in Type 2 diabetic patients. The fact that eplerenone is much better tolerated open the possibility of this therapy in cardiovascular, as well as in renal disease.

Key Words: aldosterone blockers • spironolactone • eplerenone • arterial hypertension • target organ damage

References

• Alderman MH, Madhavan S., Ooi WL, Cohen H., Sealey JE, Laragh JH Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991;324:1098-104.[Abstract]
• Berck BC, Vekstein V., Gordon HM, Tsuda T. Angiot A ensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989;13:305-14.[Abstract/Free Full Text]
• Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-8.[Abstract/Free Full Text]
• Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995;95:995-1001.[Web of Science][Medline] [Order article via Infotrieve]
• Brilla C., Weber K. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.[Abstract/Free Full Text]
• Rocha R., Chander C., Khanna K., Zuckerman A., Stier C. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-8.[Abstract/Free Full Text]
• Taddei S.,Virdis A., Mattei R. Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-33.forms of human hyperten[Abstract/Free Full Text]
• Blacher J., Amah G., Girerd X. et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-34.[Web of Science][Medline] [Order article via Infotrieve]
• Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I. Hypertension 1998;32: 965-71.[Abstract/Free Full Text]
• Delyani JA Mineralcorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Funder J. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am Heart J 2002;144:S8-S11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Corvol P.,Michaud A., Ménard J., Freifeld M., Mahoudeau J. Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology 1975;97:52-8.[Abstract/Free Full Text]
• Ménard J., Weil B., Safar Metal. Bases physiopathologiques du diagnostic et du traitement de l'hyperaldostéronisme primaire. Acquisitions Médicales Récentes 1970;321-42.
• Staessen J., Lijnen P., Fagard R., Verschueren LV, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:460-5.
• Struthers AD Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.[CrossRef][Medline] [Order article via Infotrieve]
• Pitt B., Zannad F., Remme W. et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.[Abstract/Free Full Text]
• Young WF Jr. Minireview: Primary aldosteronism - Changing concepts in diagnosis and treatment. Endocrinology 2003;144:2208-13.[Abstract/Free Full Text]
• De Gasparo M., Joss U., Ramjoue S. et al.Three new epoxyspironolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.[Abstract/Free Full Text]
• Pitt B., Remme W., Zannad F. et al., for the Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med 2003;348:1309-21.[Abstract/Free Full Text]
• Laragh JH, Sealy JE K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. Hypertension 2001;37: 806-10.[Free Full Text]
• .SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly program (SHEP). JAMA 1991;265:3255-64.[Abstract/Free Full Text]
• Weinberger MH, Roniker B., Krause SL, Weiss RJ Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Krum H., Nolly H.,Workman D. et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.[Abstract/Free Full Text]
• White WB, Duprez D., Hillaire RS et al. Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension. Hypertension 2003;41:1021-6.[Abstract/Free Full Text]
• Pitt B., Reichek N., Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation 2003;108:1831-8.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 5, No. 1, 23-25 (2004)
DOI: 10.3317/jraas.2004.002


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sierra, C. Articles by Ruilope, L. M Search for Related Content PubMed PubMed Citation Articles by Sierra, C. Articles by Ruilope, L. M Social Bookmarking                         What's this?